LSA
TAK icon

Lion Street Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Lion Street Advisors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-156
Closed -$2K – 365
2020
Q1 		$2K Buy
+156
New +$2.83K 0.01% 353

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Lion Street Advisors's TAK Position: Q2 2020 in Review

Lion Street Advisors sold out of Takeda Pharmaceutical (TAK) in Q2 2020, closing a stake of 156 shares — an estimated $2K sold.

Lion Street Advisors first reported a position in TAK in Q1 2020 and held it in 1 quarter. The position peaked at $2K in Q1 2020. 309 funds tracked by Wall St. Rank hold TAK as of Q2 2020.

  • Lion Street Advisors reported no remaining Takeda Pharmaceutical position as of Q2 2020 after selling out during the quarter.
  • Lion Street Advisors sold 156 Takeda Pharmaceutical shares in Q2 2020, an estimated $2K.
  • Lion Street Advisors first reported a position in Takeda Pharmaceutical in Q1 2020 and held it in 1 quarter.
  • Lion Street Advisors's Takeda Pharmaceutical position peaked at $2K in Q1 2020.
  • 309 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2020.

Based on Lion Street Advisors's 13F filing for Q2 2020, filed 20 Jul 2020.